Medigen Vaccine Biologics Valuation

Is 6547 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6547 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6547's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6547's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6547?

Key metric: As 6547 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6547. This is calculated by dividing 6547's market cap by their current revenue.
What is 6547's PS Ratio?
PS Ratio	19.4x
Sales	NT$648.17m
Market Cap	NT$12.59b

6547 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.2x
Enterprise Value/EBITDA	-21.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6547's PS Ratio compare to its peers?

The above table shows the PS ratio for 6547 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	23.5x
4726 Mycenax Biotech	13.9x	n/a	NT$9.3b
4162 PharmaEngine	16.2x	-8.0%	NT$13.5b
4157 TaiGen Biopharmaceuticals Holdings	60.6x	n/a	NT$9.0b
3176 Medigen Biotechnology	3.4x	n/a	NT$4.8b
6547 Medigen Vaccine Biologics	19.4x	n/a	NT$12.6b

Price-To-Sales vs Peers: 6547 is good value based on its Price-To-Sales Ratio (19.4x) compared to the peer average (23.5x).

Price to Sales Ratio vs Industry

How does 6547's PS Ratio compare vs other companies in the TW Biotechs Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
3176 Medigen Biotechnology	3.4x	n/a	US$147.42m
4169 TCM Biotech International	4.2x	n/a	US$108.31m
4160 Genetics Generation Advancement	3.4x	n/a	US$69.42m
3164 GenMont Biotech Incorporation	4.7x	n/a	US$53.20m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6547 is good value based on its Price-To-Sales Ratio (19.4x) compared to the TW Biotechs industry average (20.9x).

Price to Sales Ratio vs Fair Ratio

What is 6547's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6547 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6547's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

RBC Bioscience

NT$254.3m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.60

-0.5%

29.8%

YungShin Global Holding

NT$15.4b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$57.90

8.2%

27.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%